Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. Designing trials for patients with tumors that do not respond or stop responding to treatment with immunotherapy combinations, however, is challenging without uniform definitions of resistance. Previously, the Society for Immunotherapy of Cancer (SITC) published consensus definitions for resistance to single-agent anti-programmed cell death protein 1 (PD-1). To provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance to ICI-based combinations, SITC convened a follow-up workshop in 2021 to develop consensus definitions for resistance to multiagent ICI combinations. This manuscript reports the consensus clinical definitions for combinations of ICIs and chemotherapies. Definitions for resistance to ICIs in combination with targeted therapies and with other ICIs will be published in companion volumes to this paper.

[1]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[2]  Benjamin Wolfson,et al.  From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment , 2021, Frontiers in Oncology.

[3]  T. Powles,et al.  ctDNA guiding adjuvant immunotherapy in urothelial carcinoma , 2021, Nature.

[4]  Lisa M. Ebert,et al.  Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies , 2021, Cancers.

[5]  Michal Sheffer,et al.  Considerations for treatment duration in responders to immune checkpoint inhibitors , 2021, Journal for ImmunoTherapy of Cancer.

[6]  R. Sullivan,et al.  Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort , 2021, Journal for ImmunoTherapy of Cancer.

[7]  S. Friesland,et al.  Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. , 2021, European journal of cancer.

[8]  P. Ascierto,et al.  Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) , 2019, Nature Medicine.

[9]  S. Molina-Pinelo,et al.  Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy , 2020, Cancers.

[10]  O. Molinier,et al.  Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab , 2020, Journal of clinical medicine.

[11]  S. Grupp,et al.  Lingering effects of chemotherapy on mature T cells impair proliferation. , 2020, Blood advances.

[12]  C. Robert,et al.  Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm , 2020, Nature Reviews Clinical Oncology.

[13]  M. Verma,et al.  Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy , 2020, Oncology reviews.

[14]  Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for immunotherapy of cancer.

[15]  M. Hellmann,et al.  Acquired Resistance to Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[16]  Vanessa M. Hubbard-Lucey,et al.  Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce , 2020, Journal for ImmunoTherapy of Cancer.

[17]  A. Gao,et al.  Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. , 2020, Current opinion in endocrine and metabolic research.

[18]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[19]  S. Shah,et al.  Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study , 2019, Annals of Oncology.

[20]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[21]  R. Bell,et al.  Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.

[22]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[23]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[24]  W. J. Valente,et al.  Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA , 2018, Nature Communications.

[25]  Deric M. Park,et al.  Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[26]  Qiaohong Wang,et al.  Pseudoprogression and hyperprogression after checkpoint blockade , 2018, International immunopharmacology.

[27]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[28]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[29]  Jing Zhao,et al.  Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? , 2017, Oncotarget.

[30]  Behzad Baradaran,et al.  The Different Mechanisms of Cancer Drug Resistance: A Brief Review , 2017, Advanced pharmaceutical bulletin.

[31]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[32]  Arun Ahuja,et al.  Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer , 2016, bioRxiv.

[33]  Yu Sun Tumor microenvironment and cancer therapy resistance. , 2016, Cancer letters.

[34]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[35]  J. Wargo,et al.  Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy , 2016, Current Oncology Reports.

[36]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[37]  K. Horgan,et al.  Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer , 2016, Breast Cancer Research.

[38]  R. Sullivan,et al.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. , 2015, Seminars in oncology.

[39]  L. Zitvogel,et al.  Molecular mechanisms of ATP secretion during immunogenic cell death , 2013, Cell Death and Differentiation.

[40]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[41]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[42]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[43]  C. Mackall,et al.  Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. , 1997, Blood.

[44]  N. Nissen,et al.  Anthracycline resistance. , 1989, Acta oncologica.